← Leaderboards
Zachary David Aron
Harvard University (Medical School)
$7,720,492
Attributed
$7,936,838
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,936,838 · 8
By mechanism
R01$4,705,631 · 1
R43$3,123,364 · 6
F32$107,843 · 1
Top collaborators
- Shiva Shahrara2 shared
Most similar at Harvard University (Medical School)
Same institution · by research overlap
- Johannes Walter$13,805,708
- Ryoma Ohi$5,369,222
- Fei Liu$252,430
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyIn VivoInhibitor/AntagonistBasePharmaceutical PreparationsLeadIn VitroEvaluationSerumDrug KineticsPre-ClinicalExhibitsAnalogInfectionLiver MicrosomesToxic EffectCytotoxicityAnimal ModelSeriesBindingFutureMouse ModelPermeabilityLibraries
Grant awards (18)
Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype$298,323
R43 · FY2021 · AI · contact PI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,058,081
R01 · FY2020 · AI · contact PI
Development of a New Class of Hepatitis B Virus Inhibitors that Induce a Novel Defective Nucleocapsid Phenotype$298,483
R43 · FY2020 · AI · contact PI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,100,543
R01 · FY2019 · AI · contact PI
Synergistic panfiloviral entry inhibiting antibody drug conjugates$300,000
R43 · FY2019 · AI · contact PI
EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae$299,659
R43 · FY2019 · AI · contact PI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,114,898
R01 · FY2018 · AI · contact PI
Synergistic panfiloviral entry inhibiting antibody drug conjugates$300,000
R43 · FY2018 · AI · contact PI
EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae$297,193
R43 · FY2018 · AI · contact PI
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$208,072
R43 · FY2018 · AG · contact PI
Oxadiazole Inhibitors of Non-Stop Ribosome Rescue to treat MDR Neisseria gonorrhoeae$1,432,109
R01 · FY2017 · AI · contact PI
Novel beta-lactams as inhibitors of ebola virus infections$297,415
R43 · FY2017 · AI · contact PI
Development of small molecule TLR5 inhibitors for rheumatoid arthritis therapy$224,621
R43 · FY2017 · AG · contact PI
Novel beta-lactams as inhibitors of ebola virus infections$304,394
R43 · FY2016 · AI · contact PI
Small Molecule Inhibitors of trans-Translation with Broad Spectrum Antibacterial$295,204
R43 · FY2015 · AI · contact PI
The Promiscuity of EpoC Towards Polymer Bound Substrates$20,799
F32 · FY2007 · GM · contact PI
The Promiscuity of EpoC Towards Polymer Bound Substrates$45,976
F32 · FY2006 · GM · contact PI
The Promiscuity of EpoC Towards Polymer Bound Substrates$41,068
F32 · FY2004 · GM